Lynparza (olaparib)

pill
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Lynparza (olaparib)

How to buy Lynparza: You can order Lynparza (olaparib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer AstraZeneca
Disease Ovarian Cancer
Indication Deleterious BRCA mutation associated with advanced ovarian cancer
Mode of Action PARP inhibitor (chemotherapy)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Strength 50 mg

Who is olaparib for?

Lynparza (olaparib) is indicated as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer [1][2][3] who are in response (complete response or partial response) after platinum-based chemotherapy [2][3].

Recommended dose

Complete information about Lynparza (olaparib) dosage and administration can be found here [1][2][3]
The standard dosage is:
  • 400 mg  (8 capsules) taken twice daily.
Continue treatment until disease progression or unacceptable toxicity.
Consult your treating doctor for personalised dosing.

What is olaparib and how does it work?

Lynparza (olaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer [1][2][3] who are in response (complete response or partial response) after platinum-based chemotherapy [2][3].
Approximately 15 to 20 % of patients with ovarian cancer have a BRCA gene mutation. BRCA genes are involved in the reparation of damaged DNA and normally work to prevent tumour development. However, mutations of these genes may lead to certain cancers, including ovarian cancers. Lynparza (olaparib) is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the cancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a slowdown or stoppage of tumour growth [4].

What is olaparib's approval status?

Lynparza (olaparib) was approved by:
  • FDA (USA) on December 19, 2014 [5]
  • EMA (EU) on January 9, 2015 [6]
  • TGA (AUS) on October 13, 2016 [7]
for deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer.
The FDA approval was based on a single-arm study involving 137 patients with measurable, gBRCAm associated ovarian cancer treated with three or more prior lines of chemotherapy. The objective response rate (ORR) was 34 % (95 CI: 26, 42) with 2 % complete response and a median duration of response (mDOR) of 7.9 months (95 % CI: 5.6, 9.6) [1].
The EMA and TGA approvals were based on a double-blind placebo-controlled trial which involved 136 ovarian cancer patients with detected BRCA mutation who were in response following completion of two or more previous platinum-containing chemotherapy. The progression-free survival (PFS) was 12.2 months in the olaparib group and 4.3 in the placebo group. There was no statistically significant difference in the overall survival [2][3].
The most common side effects are fatigue (tiredness), nausea (feeling sick), vomiting, diarrhoea, dyspepsia (heartburn), headache, taste disturbances, decreased appetite, dizziness, anaemia (low red blood cell counts), lymphopenia and neutropenia (low counts of certain types of white blood cell), mean corpuscular volume elevation (increase in the average size of red blood cells) and increase in creatinine (high levels of creatinine in blood indicates problems with kidney function) [6].
References
[1] Summary of Product Characteristics [FDA]: Lynparza (olaparib), Astra Zeneca, Oct. 2016.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206162s002lbl.pdf
[2] Summary of Product Characteristics [EMA]: Lynparza (olaparib), Astra Zeneca, Jun. 2017.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003726/WC500180151.pdf
[3] Summary of Product Characteristics [TGA]: Lynparza (olaparib), Astra Zeneca, Oct. 2016.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-01055-1
[4] FDA News Release: FDA grants accelerated approval to new treatment for advanced ovarian cancer, 19/12/2016.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm
[5] Drugs.com. Lynparza, (last update: 15/11/2016), cited on 20/06/2017.
https://www.drugs.com/lynparza.html
[6] EMA. Human Medicines: Lynparza (olaparib), 9/01/2015 (last update: 14/06/2017), cited on 20/06/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/human_med_001831.jsp&mid=WC0b01ac058001d124
[7] TGA Public Summary. 13/10/2016, cited on 21/06/2017.
https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=17BBB1B546D535AECA25804B003C9CFF&agid=(PrintDetailsPublic)&actionid=1

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.